Back to Search
Start Over
Optimal Medical Therapy for Chronic Coronary Disease in 2024: Focus on Antithrombotic Therapy
- Source :
- Medical Clinics of North America; May 2024, Vol. 108 Issue: 3 p489-507, 19p
- Publication Year :
- 2024
-
Abstract
- Antiplatelet therapy is the cornerstone of the secondary prevention of cardiovascular disease. Aspirin is indicated for all patients with chronic coronary disease to prevent recurrent ischemic events. A more potent antithrombotic therapy—including P2Y12 inhibitor monotherapy, dual antiplatelet therapy, or vascular dose anticoagulation—reduces the risk of ischemic events but also increases bleeding risk. Clinicians must weigh both ischemic risks and bleeding risks when determining an optimal antithrombotic therapy for patients with chronic coronary disease, and soliciting patient involvement in shared decision-making is critical.
Details
- Language :
- English
- ISSN :
- 00257125
- Volume :
- 108
- Issue :
- 3
- Database :
- Supplemental Index
- Journal :
- Medical Clinics of North America
- Publication Type :
- Periodical
- Accession number :
- ejs64755485
- Full Text :
- https://doi.org/10.1016/j.mcna.2023.11.004